FMP
Humana Inc. (NYSE:HUM) Faces Legal and Market Challenges
Jul 18, 2025 7:00 PM - Danny Green
Image credit: Google Images
- Stephen Baxter from Wells Fargo set a price target of $348 for NYSE:HUM, indicating a potential increase of about 60.27%.
- A Texas federal judge dismissed a lawsuit filed by Humana, challenging the reduction of its Medicare plan star ratings.
- Despite recent legal setbacks and market volatility, Humana's stock shows signs of continued investor interest with a trading volume of 3,399,907 shares.
Humana Inc. (NYSE:HUM) is a leading health insurance company in the United States, primarily known for its Medicare plans. The company provides a range of health insurance products and services, including government-funded Medicare plans. Humana competes with other major health insurers like UnitedHealth Group and Anthem in the Medicare market.
On July 18, 2025, Stephen Baxter from Wells Fargo set a price target of $348 for HUM. At that time, the stock was priced at $217.14, suggesting a potential increase of about 60.27%. Currently, the stock is priced at $219.28, reflecting a slight increase from the initial announcement but still far from the target.
Recently, a Texas federal judge dismissed a lawsuit filed by Humana. The lawsuit challenged the U.S. Department of Health and Human Services' decision to reduce Humana's star ratings for its Medicare plans. This legal development is significant for Humana as it continues to navigate its relationship with federal health authorities.
The stock has shown volatility, with today's price fluctuating between $206.87 and $223.84. Over the past year, HUM has seen a high of $406.46 and a low of $206.87. The company's market capitalization is approximately $26.47 billion, indicating its substantial presence in the health insurance industry.
Today's trading volume for HUM is 3,399,907 shares on the NYSE. Despite the recent legal setback, the stock's performance and trading activity suggest continued investor interest. The market will be closely watching how Humana addresses the challenges related to its Medicare plan ratings.
Other Blogs
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
Dec 17, 2024 8:58 AM - Sanzhi Kobzhan
Examining Tesla’s Financial Health Using FinancialModelingPrep’s Ratios API
Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...
Dec 22, 2024 7:59 AM - Sanzhi Kobzhan
Two great Software Platform Stocks Similar to Palantir (PLTR)
When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...
